EXPLORE!

FDA approves new drug Yorvipath for hypoparathyroidism, a rare disorder

  429 Views

Emedinexus    24 March 2025

The U.S. Food and Drug Administration has approved Yorvipath injection for subcutaneous use in adults with hypoparathyroidism. Yorvipath was not studied in adults with acute post-surgical hypoparathyroidism.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.